Global Lennox-Gastaut Syndrome Treatment Market Size, Status and Forecast 2021-2027

Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG). Typically, it presents in children aged 3–5 years and can persist into adulthood.
Corpus callosotomy is a surgical procedure used for treating refractory generalized seizures caused due to Lennox-Gastaut syndrome (LGS). However, this surgical procedure involves craniotomy with microdissection. Therefore, companies are focusing on the development of minimally invasive procedures such as MR-guided laser interstitial thermal therapy (MRg-LITT). MRg-LITT has emerged as a safe, effective, and durable alternative of traditional open corpus callosotomy. The efficacy of MRg-LITT is also being tested in advanced surgical ablation of epileptogenic foci and corpus callosotomy. This will further boost its adoption in LGS treatment. Such advancements in surgical treatments will be one of the key trends that will impact LGS market growth in the coming years.

Market Analysis and Insights: Global Lennox-Gastaut Syndrome Treatment Market
The global Lennox-Gastaut Syndrome Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Lennox-Gastaut Syndrome Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Lennox-Gastaut Syndrome Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Lennox-Gastaut Syndrome Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Lennox-Gastaut Syndrome Treatment market.

Global Lennox-Gastaut Syndrome Treatment Scope and Market Size
Lennox-Gastaut Syndrome Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Lennox-Gastaut Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Non-surgical Treatment
Surgical Treatment

Segment by Application
Seizures
Ocular Abnormality
EEG Findings
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Eisai Co., Ltd.
GlaxoSmithKline plc.
H. Lundbeck A/S
Johnson & Johnson Services, Inc.
Supernus Pharmaceuticals, Inc